Top

Published in:

01-01-2021 | Epigenetics | Surgical Symposium Contribution

Multifocal Small Bowel Neuroendocrine Tumours

Author: Janice L. Pasieka

Published in: World Journal of Surgery | Issue 1/2021

Abstract

In contemporary surgical series, the incidence of multifocal tumours (MFT) in small bowel neuroendrocrine tumours (SBNET) is as high as 50%. Familial forms of SBNET appear to have an even higher rate of MFTs in the range of 80%. Multifocal disease poses several challenges and questions for the operating surgeon, including the cause of the disease whether it is local metastases or a genetic field defect, the extent of the resection, and the prognosis. The etiology of these multiple tumours appears to be multifactorial and may represent localized metastases in some, a genetic mutation resulting in the rare familial form of this disease in others, or the integration of genetic and epigenetic events within the bowel. Contrary to historical series, recent data suggest that MFT are not associated with a poorer prognosis. The challenge remains on the long-term surveillance of these unique tumours.

Saleh MA, Mansoor E, Anindo M et al (2019) Prevalence of small intestine carcinoid tumors: a us population-based study 2012–2017. Dig Dis Sci 64:1328–1334CrossRef

Moertel CG, Sauer WG, Dokkert MB et al (1961) Life history of the carcinoid tumour of the small intestine. Cancer 14:901–912CrossRef

Yantiss RK, Odze RD, Farrave FA et al (2003) Solitary versus multiple carcinoid tumors of the ileum. Am J Surg Pathol 27:811–817CrossRef

Burke AP, Thomas RM, Elsayed AM et al (1997Carcinoids) Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathological study of 167 cases. Cancer 79:1086–1093CrossRef

Choi AB, Maxwell JE, Keck KJ et al (2017) Is multifocality an indicator of aggressive behavior in small bowel neuroendocrine tumors? Pancreas 46(9):1115–1120. https://doi.org/10.1097/MPA.0000000000000911CrossRefPubMedPubMedCentral

Gangi A, Siegel E, Barmparas G et al (2018) multifocality in small bowel neuroendocrine tumors. J Gastrointest Surg 22:303–309CrossRef

Hughes MS, Azoury SC, Assadipour Y et al (2016) Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs). Surgery 159(1):350–356. https://doi.org/10.1016/j.surg.2015.05.041CrossRefPubMed

Stalberg P, Westin G, Thirlwell C (2016) Genetics and epigenetics in small intestinal neuroendocrine tumours. J Intern Med 280(584):594

Sei Y, FengJ ZX et al (2016) Polyclonal crypt genesis and development of familial small intestinal neuroendocrine tumors. Gastroenterology 151(1):140–151. https://doi.org/10.1053/j.gastro.2016.03.007CrossRefPubMedPubMedCentral

10.

Wang YZ, Carrasquillo JP, McCord E et al (2014) Reappraisal of lymphatic mapping for midgut neuroendocrine patients undergoing cytoreductive surgery. Surgery 156:1498–1503CrossRef

11.

Guo Z, Li Q, Wilander E, PonteÂn J et al (2000) Clonality analysis of multifocal carcinoid tumours of the small intestine by X-chromosome inactivation analysis. J Pathol 190:76–79CrossRef

12.

Katona TM, Jones TD, Wang M et al (2006) Molecular evidence for independent origin of multifocal neuroendocrine tumors of the enteropancreatic axis. Cancer Res 66(9):4936–4942CrossRef

13.

Berge T, Linell F (1976) Carcinoid tumours. frequency in a defined population during a 12 year period. Acta Pathol Microbiol Scand A 84:322–330PubMed

14.

Banck MS, Kanwar R, Kulkarni AA et al (2013) The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest 123:2502–2505CrossRef

15.

Crona J, Gustavsson T, Norlén O et al (2015) Somatic mutations and genetic heterogeneity at the CDKN1B locus in small intestinal neuroendocrine tumors. Ann Surg Oncol 3:1428–1435CrossRef

16.

Francis JM, Kiezun A, Ramos AH et al (2013) Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet 45(12):1483–1486. https://doi.org/10.1038/ng.2821CrossRefPubMedPubMedCentral

17.

Scarpa A (2019) The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours. Annales d’Endocrinologie 80:153–158CrossRef

18.

Karpathakis A, Dibra H, Pipinikas C et al (2016) Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor. Clin Cancer Res 22(1):250–258CrossRef

19.

Howe JR, Merchant NB, Conrad C et al (2020) The north american neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49(1):1–33. https://doi.org/10.1097/MPA.0000000000001454CrossRefPubMed

20.

Zaidi MY, Lopez-Aguiar AG, Dillhoff M et al (2019) Prognostic role of lymph node positivity and number of lymph nodes needed for accurately staging small-bowel neuroendocrine tumors. JAMA Surg 154(2):134–140. https://doi.org/10.1001/jamasurg.2018.3865CrossRefPubMed

21.

Grandhi MS, Lafaro KJ, Pawlik TM (2015) Role of logo regional and systemic approaches for the treatment of patients with metastatic neuroendocrine tumors. J Gastrointest Surg 19(12):2273–2282CrossRef

22.

Niederle B, Pape U, Costa F et al (2016) ENAETs consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 103:125–138CrossRef

23.

Kasai Y, Mahuron K, Hirose K et al (2019) Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumor. J Surg Oncol 120:1311–1317CrossRef

24.

Landry CS, Lin HY, Phan A et al (2013) Resection of at risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg 37:1695–1700. https://doi.org/10.1007/s00268-013-1918-8CrossRefPubMed

25.

Bilimoria KY, Bentrem DJ, Wayne JD et al (2009) Small bowel cancer in USA; changes in epidemiology, treatment and survival over last 20 years. Ann Surg 249:63–71CrossRef

26.

Ito T, Igarashi H, Nakamura K et al (2015) Epidemiological trends in pancreatic and gastrointestinal neuroendocrine tumors in Japan. J Gastroenterol 50:58–64CrossRef

27.

Le Roux C, Lombard-Bohas C, Delmas C et al (2011) Relapse factors for ileal neuroendocrine tumours after curative surgery: a retrospective French multicentre study. Dig Liver Dis 43:828–833 [PubMed: 21641888]CrossRef

28.

Singh S, Chan DL, Moody L et al (2018) 2Recurrence in resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol 4(4):583–585CrossRef

29.

Singh S, Moody L, Chan DL et al (2018) Follow-up recommendations for completely resected gastroenteropancreatic neuroendocrine tumors. JAMA Oncol 4(11):1597–1604CrossRef

30.

Strosberg JR, Halfdanarson TR, Bellizzi AM et al (2017) The north american neuroendocrine society (nanets) consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 46(6):707–714. https://doi.org/10.1097/MPA.0000000000000850CrossRefPubMedPubMedCentral

Title: Multifocal Small Bowel Neuroendocrine Tumours
Author: Janice L. Pasieka
Publication date: 01-01-2021
Publisher: Springer International Publishing
Keyword: Epigenetics
Published in: World Journal of Surgery / Issue 1/2021
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-020-05663-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Multifocal Small Bowel Neuroendocrine Tumours

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

The Fun Factor: Does Serious Gaming Affect the Volume of Voluntary Laparoscopic Skills Training?

Esophageal Lipoma and Liposarcoma: A Systematic Review

Geometry of Sleeve Gastrectomy Measured by 3D CT Versus Weight Loss: Preliminary Analysis

Prognostic Utility of the Glasgow Prognostic Score for the Long-Term Outcomes After Liver Resection for Intrahepatic Cholangiocarcinoma: A Multi-institutional Study

Patient-Centered Surgical Care Meets the Social Determinants of Health

European Society for Clinical Nutrition and Metabolism (ESPEN) Malnutrition Criteria for Predicting Major Complications After Hepatectomy and Pancreatectomy